You are here

Field Deployable Diagnostic Test for Active Cutaneous Leishmania and a Test for Latent Infection

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-05-C-0020
Agency Tracking Number: A043-177-1132
Amount: $69,999.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: A04-177
Solicitation Number: 2004.3
Solicitation Year: 2004
Award Year: 2005
Award Start Date (Proposal Award Date): 2004-12-09
Award End Date (Contract End Date): 2005-06-09
Small Business Information
2033 Route 130
Monmouth Jct., NJ 08852
United States
DUNS: 116671434
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: Yes
Principal Investigator
 Hyeonsuk Kim
 (732) 297-2222
Business Contact
 Young Choi
Title: President
Phone: (732) 297-2222
Research Institution

Leishmaniasis has significant impact on military and civilian populations throughout the Asia-Africa region, including Afghanistan and Iraq. There are currrentlly no proper field-deployable diagnostic tools for the key form, cutaneous leishmaniasis. Development of an assay which detects cutaneous leishmaniasis, that is rapid, accurate, field usable, soldier-friendly, and meets regulatory requirements is a high priority for DoD and also a priority for health and government medical centers responsible for inhabitants and visitors to the region. Access Bio proposes to develop and commercialize a rapid diagnostic test for military and civilian use. Immediate benefits include the ability to detect cutaneous leishmaniasis on a disease-stage basis (acute/chronic) and generation of revenues to a US small business concern. Downstream potential benefits include utilization of the knowledge to develop a useful monitoring kit for a leishmaniasis vaccine currently under development and application and modification of the current research and development approach to other parasitic diseases in the future.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government